Cortexin Peptide Reduced Brain Damage After Stroke by Lowering Oxidative Stress in Rats | Research

The takeaway

The neuropeptide preparation Cortexin reduced oxidative stress and modulated inflammatory and calcium signaling biomarkers in rat brain tissue after experimentally induced stroke.

Significant oxidative stress reduction
Cortexin lowered total oxidant status and raised total antioxidant status in brain tissue after ischemia-reperfusion injury in rats

What the researchers found

In rats subjected to cerebral ischemia-reperfusion injury, Cortexin treatment significantly reduced total oxidant status (TOS) and increased total antioxidant status (TAS) compared to untreated injury groups. The ischemia and I/R groups showed significantly elevated TOS (p = 0.012 and p = 0.005) and decreased TAS (p = 0.000) versus controls.

Cortexin also modulated the expression of key biomarkers in brain tissue: OPG (a protective factor against cell death), RANK/RANKL (inflammatory signaling), and TRPC1 (calcium channel involved in neuronal function). The effects were observed at both 1 mg/kg and 2 mg/kg doses. However, some inflammatory markers remained elevated despite treatment, suggesting Cortexin partially but not completely reversed the inflammatory response.

Why it matters

Stroke is a leading cause of death and disability worldwide, and the damage that occurs when blood flow is restored (reperfusion injury) has no targeted treatment. Cortexin has been used clinically in Russia and some Eastern European countries for decades for neurological conditions, but its mechanisms have been poorly understood. This study provides molecular evidence for how it might protect the brain — through antioxidant effects and modulation of inflammatory and calcium signaling pathways — which could support its investigation in more rigorous clinical trials.

The numbers in context

n=35 rats; 5 groups of 7; 45-min ischemia + 7-day reperfusion; TOS p=0.012/0.005; TAS p=0.000; 1 and 2 mg/kg Cortexin doses

How the study worked

35 male Wistar rats divided into 5 groups: control, ischemia only (45 minutes), ischemia-reperfusion (7 days), and two Cortexin treatment groups (1 mg/kg and 2 mg/kg during reperfusion). On day 8, brain tissue was analyzed by immunohistochemistry for OPG, RANK, RANKL, and TRPC1 expression. Serum total oxidant status (TOS) and total antioxidant status (TAS) were measured by ELISA.

Who was studied

35 male Wistar albino rats in a cerebral ischemia-reperfusion injury model

What this study cannot tell us

This was a small animal study (35 rats, 7 per group), which limits statistical power. The abstract contains apparent formatting errors in the p-values, making some results difficult to interpret. Cortexin is a complex mixture of peptides, not a single defined molecule, which complicates mechanistic interpretation. The 7-day treatment period is short. No behavioral or functional outcomes were measured — only biomarker expression. The study was not blinded according to the abstract. Results from rat stroke models frequently fail to translate to human stroke treatment.

How to read the evidence

Rated preliminary because this is a small (n=35) rat study without blinding or functional outcome measures. While it provides mechanistic insights into Cortexin's potential neuroprotective pathways, the study design limitations and the known poor translation rate of rodent stroke models to human treatment limit the evidence strength.

When this study was published

Published in 2025, this is current research contributing to the ongoing effort to establish molecular mechanisms for Cortexin. The study is relevant to discussions about whether peptide bioregulators deserve more rigorous clinical investigation in Western medical frameworks.

The bigger picture

Cortexin is part of a tradition of peptide bioregulators developed primarily in Russian science — preparations derived from animal organ tissues that contain mixtures of short peptides. While widely used in some countries, they lack the rigorous Phase III trial data required for approval in Western markets. This study contributes to a growing body of mechanistic research attempting to explain how these preparations work at the molecular level, potentially bridging the gap between traditional use and evidence-based medicine.

Questions still open

Would Cortexin show neuroprotective effects in a more rigorous, blinded, pre-clinical stroke study with functional outcome measures?
Which specific peptides within the Cortexin mixture are responsible for the observed antioxidant and anti-inflammatory effects?
Could the OPG/RANK/RANKL and TRPC1 modulation observed here be replicated with a defined synthetic peptide rather than a tissue-derived mixture?

Common questions

What is Cortexin?

Cortexin is a neuropeptide preparation made from animal brain tissue (typically from young cattle or pigs). It contains a mixture of short peptides and is used in Russia and some Eastern European countries to treat neurological conditions including stroke, traumatic brain injury, and cognitive impairment. It's classified as a peptide bioregulator — part of a tradition of tissue-derived peptide medicines.

Why study OPG/RANK/RANKL in the brain — isn't that a bone pathway?

The OPG/RANK/RANKL system was first discovered in bone, where it controls bone remodeling. But researchers have since found these same proteins are active in the brain, where they play roles in inflammation, cell survival, and neurodegeneration. After stroke, changes in this pathway may contribute to whether neurons survive or die, making it a relevant target for neuroprotective treatments.

Read the original research

Cortexin modulates OPG/RANK/RANKL and TRPC1 expression in cerebral ischemia-reperfusion injury.

Neurological research, 1-12

View on PubMed ↗Publisher’s paper ↗

Citation

Guven, Cengiz; Türk, Ahmet; Koçak, Seda; Zencirci, Busra; Yalcin, Alper; Aydın, Hasan; Doğukan, Mevlut. (2025). Cortexin modulates OPG/RANK/RANKL and TRPC1 expression in cerebral ischemia-reperfusion injury.. Neurological research, 1-12. https://doi.org/10.1080/01616412.2025.2536075